CAT Catco Reinsurance Opportunities Fund Limited

25.00

0.00 (0.00%)

10 Oct 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Catco Reinsurance Opportunities Fund Limited	LSE:CAT	London	Ordinary Share	BMG1961Q3242	ORD USD0.00013716 (DI)

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	25.00	14.00	36.00	25.00	25.00	25.00	0.00	01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Unit Inv Tr, Closed-end Mgmt	6.33M	5.44M	3.6440	6.86	37.33M

Cambridge Antibody - Acquisition, etc.

16/07/1998 9:42am

UK Regulatory

RNS No 3885q
CAMBRIDGE ANTIBODY TECHNOLOGY
16th July 1998

                  ACQUISITION OF APTEIN INC. CLOSED
                                &
   APPROVAL OF EUROPEAN PATENT FOR POLYSOME DISPLAY RECEIVED

Melbourn, UK:  Cambridge Antibody Technology Group plc (CAT) today announces
that it has closed the deal for the purchase of US company, Aptein Inc. and in
addition Aptein's European patent for its polysome display technology was
granted on 15 July 1998.

The purchase of this US Company, announced on 23 June 1998, provides CAT with
a powerful extension to its existing antibody display technology.  Aptein now
has granted US, European and Australian patents which dominate the field of
polysome display.

For Further Information Contact:
Cambridge Antibody Technology Group Plc
Dr David Chiswell, Chief Executive Officer        Tel: +44 (0) 1763 203233

City/Financial Enquiries
HCC.DeFacto, Nicola How                           Tel: +44 (0) 171 496 3300

Trade/Scientific Press Enquiries
HCC.DeFacto, Andrew Worsfold                      Tel: +44 (0) 1223 518093

END

ACQDQFBFVDKZBKD